Biotechnology

LOS ANGELES (Reuters)-a pivotal trial of experimental cancer targeting antibody Seattle Genetics for sick and UN Crowfoot Hodgkin the study found that more than a third country realized all point reduction of cancer. The company also said he hopes to submit the drug, brentuximab vedotin, u. s. regulator in the first half of next year for the sick and night Crowfoot Hodgkin or the UN UN large cell anaplastic (ALCL) who suspended in response to other thérapies. The company was a précédemment soumission would in the first half of 2011. Was '' our goal should submit in the first season, there is a review accéléré economic and trade market in 2011, "Chief Executive of Clay Siegall Seattle genetics said in an interview by telephone. Judging by vedotin brentuximab compared with another drug, but rate reduction on all fronts for patients in the same way tends, Pasco Bachelor, he said. The company developed UN drug and medicine Takeda Co., Japan and European regulators to discuss ...

LOS ANGELES (Reuters) – a key trial Seattle Genetics tests with the patients antibodies targeting cancer n Hodgkin Lymphoma, it was found that more than a third of them achieved the complete remission of their cancer. The company also said it expects to produce drugs now, following the US regulatory authorities brentuximab vedotin (2) years from the date of the first quarter of patients either n Hodgkin Lymphoma or anaplastic large cell Lymphoma (ALCL) that have ceased responding to other therapies. The company had previously said it would take place in the first half of 2011, the consignment. "Our goal should be submitted in the first quarter of the year, and can be placed on the market of an accelerated review in 2011," Seattle Genetics CEO Siegall told Reuters the telephone Clay in the interview. The experiment to compare with another drug brentuximab vedotin, but similar patients full cancellation of the course is typically a single character, he said. The company is dev...